News Release
July 22, 2019
Sawai Pharmaceutical Co., Ltd.
Upsher-Smith Laboratories, LLC

UPSHER-SMITH LABORATORIES COMPLETES ACQUISITION OF TWO TREATMENTS
FOR ACUTE MIGRAINE IN ADULTS
Maple Grove, MN – July 20, 2019 – Upsher-Smith Laboratories, LLC (“Upsher-Smith”, President
and CEO: Rusty Field), a subsidiary of Sawai Pharmaceutical Co., Ltd. (“Sawai”, Head office:Osaka, Japan, President: Mitsuo Sawai) today announced that it has completed the acquisition ofTosymra™ (sumatriptan) Nasal Spray 10 mg, and Zembrace® SymTouch® (sumatriptan succinate)
Injection 3 mg from Dr. Reddy’s Laboratories Limited (“DRL”, Head office: Hyderabad Telangana,India, Co-Chairman and CEO: G.V. Prasad). The products were previously commercialized through
DRL’s wholly owned subsidiary, Promius Pharma LLC (“Promius”, Head office: New Jersey, USA,
President: Anil Namboodiripad). Both medications are indicated for the acute treatment of migrainewith or without aura in adults.
“More than thirty-six million Americans suffer from migraines, and Upsher-Smith is proud to be
diversifying our portfolio with two products that can bring pain relief to a significant number ofpatients suffering from acute migraine,” said Rusty Field, President and CEO, Upsher-Smith. “Wewill be working diligently to ensure the smooth delivery of Zembrace® SymTouch® to patients, and toprepare for the launch of Tosymra™, which we expect to take place toward the end of 2019.”
The addition of Tosymra™ and Zembrace® SymTouch® rounds out Upsher-Smith’s migraine
product portfolio. The Company currently offers Qudexy® XR (topiramate) Extended-Release
Capsules, a once-daily treatment for use in the prevention of migraine headache in adults andadolescents 12 years of age and older.
About Sumatriptan Formulations
Tosymra™ Nasal Spray 10 mg, and Zembrace® SymTouch® Injection 3 mg are indicated for theacute treatment of migraine with or without aura in adults.
About Migraine
Migraine is an inherited, disabling, neurological condition that leads to attacks of head pain,
sensitivity to the environment, and other neurological symptoms.1 It is the third most common andthe seventh most disabling medical disorder in the world, affecting more than 36 million Americans.1
Treatments for migraine include acute and prophylactic with the majority of patients using acutetreatments.2
1.

American Migraine Foundation. Available at:https://americanmigrainefoundation.org/resource-library/migraine-where-we-are-and-where-we-are-going/.
Accessed June 17, 2019.

2.

Decision Resources Group Report, Symphony Migraine Patient Claims Data. 2015. IMS Database.

News Release
About Upsher-Smith
Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve
the health and lives of patients through an unwavering commitment to high-quality products andsustainable growth. Since 1919, it has brought generics and brands to a wide array of customers
backed by an attentive level of service, strong industry relationships, and dedication touninterrupted supply.
As Upsher-Smith celebrates its 100-year anniversary, the company enters a new ambitious era
that has been accelerated by its 2017 acquisition by Sawai. Upsher-Smith and Sawai plan toleverage each other for growth worldwide and embark on an exciting new chapter as they seek todeliver the best value for their stakeholders, and most importantly, Do More Good™ for the patients
they serve. For more information, visit https://www.upsher-smith.com.

◆ Contact information ◆PR / IR Group, Corporate Strategy Department, Sawai Pharmaceutical Co., Ltd.
E-mail: koho@sawai.co.jp